Oxazole Derivatives for Selective Peripheral FAAH Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, inflammation, and other disorders related to fatty acid amide hydrolase (FAAH) activity lack effective inhibitors that can selectively modulate FAAH substrate levels without adverse side effects, particularly in peripheral tissues while minimizing central nervous system impact.
Innovation Solution
Development of Oxazole derivatives that act as selective inhibitors of FAAH, formulated into pharmaceutical compositions for therapeutic use in treating conditions like osteoarthritis, rheumatoid arthritis, diabetic neuropathy, and other disorders by inhibiting FAAH activity preferentially in peripheral tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FAAH inhibition is achieved to increase endogenous fatty acid amides for pain relief and anti-inflammatory effects, then therapeutic efficacy is improved, but adverse side effects occur particularly in peripheral tissues
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective tissue distribution properties. The compounds are engineered to preferentially accumulate in or act upon peripheral tissue FAAH enzymes while minimizing penetration or activity in the central nervous system. This spatial differentiation of inhibitor action allows therapeutic benefits in peripheral tissues (pain relief, anti-inflammatory effects) while avoiding CNS-related adverse side effects.
Solution Approach 2:
The patent segments the FAAH inhibition action into peripheral and central components by developing compounds with differential bioavailability. The inhibitors are designed to selectively target peripheral FAAH isoforms or compartments while leaving central FAAH activity relatively unaffected. This segmentation enables independent optimization of therapeutic efficacy in peripheral tissues while minimizing CNS toxicity.
2Ease of operation
If FAAH inhibitors are used to treat peripheral tissue conditions, then pain relief and anti-inflammatory effects are achieved, but central nervous system effects are minimized
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular properties of the oxazole derivatives to achieve desired pharmacokinetic profiles. Specific structural parameters (substituents on the oxazole ring, chain length, functional groups) are optimized to control lipophilicity, molecular weight, and other properties that govern tissue distribution. These parameter adjustments enable selective peripheral targeting without requiring overly complex molecular structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Oxazole derivatives effectively increase endogenous fatty acid amides, providing pain relief and reducing inflammation without the adverse side effects associated with other anti-lipidemic agents, while minimizing central nervous system effects.
Implementation Method 1
Oxazole derivatives effectively increase endogenous fatty acid amides, providing pain relief and reducing inflammation
Data Source
AI summary
The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.